

**BEDFORDSHIRE, LUTON AND MILTON KEYNES AREA
PRESCRIBING COMMITTEE (APC)**

Icosapent Ethyl Prescribing Guidance

Ratified by BLMK APC Sept 2022


The following organisations contribute to and participate in the BLMK APC – Bedfordshire, Luton and Milton Keynes Integrated Care Board ; Bedfordshire Hospitals NHS Foundation Trust; Cambridgeshire Community Services NHS Trust; Central and North West London NHS Foundation Trust; East London NHS Foundation Trust; Milton Keynes University Hospital NHS

Icosapent Ethyl 998mg Capsules Prescribing Guidance

The [NICE Technology Appraisal TA805](#) recommends Icosapent ethyl as an option for reducing the risk of cardiovascular events in adults with a raised **fasting** triglyceride of 1.7 mmol/litre or above and **are taking statins**, have established cardiovascular disease and a low-density lipoprotein cholesterol (LDL-C) levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre.

Full prescribing information can be found in the products [Summary of Product Characteristics](#).

Eligibility Criteria



* <https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/04/Summary-of-national-guidance-for-lipid-management-for-primary-and-secondary-prevention-of-cardiovascular-disease.pdf>